Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-07-04T13:07:34.572Z Has data issue: false hasContentIssue false

Immune heterogeneity of non-psychotic mental disorders

Published online by Cambridge University Press:  13 August 2021

S. Zozulya*
Affiliation:
Laboratory Of Neuroimmunology, Mental Health Research Centre, Moscow, Russian Federation
L. Androsova
Affiliation:
Laboratory Of Neuroimmunology, Mental Health Research Centre, Moscow, Russian Federation
I. Otman
Affiliation:
Laboratory Of Neuroimmunology, Mental Health Research Centre, Moscow, Russian Federation
T. Vetlugina
Affiliation:
Laboratory Of Clinical Psychoneuroimmunology And Neurobiology, Mental Health Research Institute, Tomsk National Research Medical Center, Tomsk, Russian Federation
V. Nikitina
Affiliation:
Laboratory Of Clinical Psychoneuroimmunology And Neurobiology, Mental Health Research Institute, Tomsk National Research Medical Center, Tomsk, Russian Federation
T. Klyushnik
Affiliation:
Laboratory Of Neuroimmunology, Mental Health Research Centre, Moscow, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Current studies indicate the involvement of inflammation in the pathogenesis of chronic non-infectious diseases, and therefore it is of interest to study the role of inflammation markers in non-psychotic mental disorders (NPMD).

Objectives

To identify a number of inflammatory markers in serum of patients with NPMD.

Methods

73 patients with NPMD were examined (F43.2; F06.6). The comparison group consisted of 76 patients with endogenous psychosis (EGP) (F20.0; F25.0). The control group included 80 healthy people. The serum activity of leukocyte elastase (LE), α1-proteinase inhibitor (α1-PI) and the level of autoantibodies (aAb) to neuroantigens were determined.

Results

Three groups of patients with different variants of inflammatory response to the pathological process were identified. In group 1 (23.3%), all indices corresponded to the control values, which indicated the absence of the pathological process in brain. In group 2, there was a significant increase in activity both LE and α1-PI compared to control (p<0.05). This type of immune reaction characterized a balanced inflammatory response. It was found in 52% of patients with NPMD and in all patients with EGP. The aAb level also exceeded the control values (p<0.05). Group 3 (24.7%) showed an increase in α1-PI activity (p<0.05), but not in LE activity compared to control. Insufficient LE activity reflects a decrease in the functional activity of neutrophils.

Conclusions

The immune heterogeneity of NPMD according to the level of inflammatory markers was identified. 52% of patients with NPMD have a pronounced activation of inflammatory reactions accompanied by increased levels of aAb to neuroantigens.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.